News
LGVN
3.250
+4.50%
0.140
Why RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
RH posted weaker-than-expected results for its fourth quarter, but issued upbeat forecast. The company's shares jumped 9.4% to $324.99 in pre-market trading. Avalo Therapeutics, Inc. Gained 256.6% on Wednesday.
Benzinga · 1d ago
Weekly Report: what happened at LGVN last week (0318-0322)?
Weekly Report · 4d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
XTL Biopharmaceuticals shares moved upwards by 95.8% to $2.04 during Wednesday's regular session. Etao International Co (NASDAQ:ETAO) stock rose 84.65% in the session. Annovis Bio (NYSE:ANVS) shares moved up by 39.12%. The company's Q4 earnings report came out yesterday.
Benzinga · 03/20 17:31
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Etao International Co (NASDAQ:ETAO) stock rose 249.4% to $0.5 during Tuesday's after-market session. The company's, Q4 earnings came out today. Taysha Gene Therapies shares moved upwards by 29.36%.
Benzinga · 03/19 21:34
Longeveron files to sell Class A common stock, warrants, no amount given
Longeveron files to sell Class A common stock, warrants, no amount given. The company filed a prospectus related to the sale of class A stock for an undisclosed amount. This prospectus is not an offer to sell these securities. Longever on Inc. (LGVN)
Seeking Alpha · 03/19 21:21
*Longeveron Offering Stock and Warrants
Dow Jones · 03/19 21:17
Longeveron Announces Reverse Stock Split Approval
TipRanks · 03/19 20:12
Longeveron approves 1-for-10 reverse stock split
Longeveron approves 1-for-10 reverse stock split of its class A common stock and class B common stock. The reverse split is intended to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq. Longever on Inc. (LGVN) Stock.
Seeking Alpha · 03/19 20:07
Longeveron Board Approves 1-for-10 Reverse Split Of Class A Common Stock
The Reverse Split was previously approved by the Company's stockholders. The Reverse Split will legally take effect on March 26, 2024. The Company's Class A common stock will open for trading on The Nasdaq Capital Market on March 27, 2024, under the ticker symbol "LGVN"
Benzinga · 03/19 20:02
*Longeveron: Shares Will Begin Trading on a Reverse Split Adjusted Basis on March 27 >LGVN
Dow Jones · 03/19 20:02
*Longeveron: Reverse Split Will Take Place 11:59 p.m. ET on March 26 >LGVN
Dow Jones · 03/19 20:02
*Longeveron Announces 1-For-10 Reverse Stk Split
Dow Jones · 03/19 20:01
Weekly Report: what happened at LGVN last week (0311-0315)?
Weekly Report · 03/18 11:44
Weekly Report: what happened at LGVN last week (0304-0308)?
Weekly Report · 03/11 11:40
Weekly Report: what happened at LGVN last week (0226-0301)?
Weekly Report · 03/04 11:44
Longeveron (LGVN) Receives a Buy from Maxim Group
TipRanks · 03/01 20:25
*Longeveron: Cost Saving Measures Include Discontinuation of Aging-related Frailty Clinical Trial in Japan, Related Staff Reductions >LGVN
Dow Jones · 02/27 21:18
*Longeveron Believes Existing Cash and Cash Equivalents Will Fund Oper Expenses and Cap Expenditures Into 2Q of 2024 >LGVN
Dow Jones · 02/27 21:18
*Longeveron Prioritizing Development of Lomecel-B in HLHS >LGVN
Dow Jones · 02/27 21:17
*Longeveron Anticipates Completing Enrollment in ELPIS II Trial in 2024 >LGVN
Dow Jones · 02/27 21:17
More
Webull provides a variety of real-time LGVN stock news. You can receive the latest news about Longeveron Inc through multiple platforms. This information may help you make smarter investment decisions.
About LGVN
Longeveron Inc. is a clinical-stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The Company is primarily focused on three pipeline indications, which include Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty. Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The Company has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.